Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03556683 · ClinicalTrials.gov registry record · NA
Phase I Assessment of Hypertonic Saline in Moderate to Severe Asthmatics
A NA study of Moderate to Severe Asthma, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- NA
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT03556683 is a NA study of Moderate to Severe Asthma that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 24 participants, below the 787-participant average among 3 other Moderate to Severe Asthma trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03556683, a NA study of Moderate to Severe Asthma, has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- NA
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
Purpose: To determine if inhaled hypertonic saline (HS) accelerates airway mucociliary clearance (MCC) in well-controlled moderate to severe asthmatics.
Conditions Studied
Interventions
- DEVICE 3% Hypertonic Saline
- DEVICE 7% Hypertonic Saline
- DRUG Salbutamol
Study Locations (1)
North Carolina
- Center for Environmental Medicine, Asthma and Lung Biology - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2018-10-01 |
| Est. Completion | 2024-06-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03556683
The ClinicalTrials.gov registry entry for NCT03556683 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 787-participant average among 3 other Moderate to Severe Asthma trials with a reported enrollment target (97% lower). The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Moderate to Severe Asthma appearing as the primary indexed condition, and to 3 interventions - of which 3% Hypertonic Saline is the first listed.
NCT03556683 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT03556683 about?
NCT03556683 is a clinical study titled "Phase I Assessment of Hypertonic Saline in Moderate to Severe Asthmatics". Purpose: To determine if inhaled hypertonic saline (HS) accelerates airway mucociliary clearance (MCC) in well-controlled moderate to severe asthmatics.
What is the current status of trial NCT03556683?
This trial is currently completed. It is a NA study. The enrollment target is 24 participants. The study started on 2018-10-01. Estimated completion is 2024-06-06.
What conditions does trial NCT03556683 study?
This clinical trial studies the following conditions: Moderate to Severe Asthma.
What interventions are being tested in trial NCT03556683?
The interventions under investigation include: 3% Hypertonic Saline (DEVICE), 7% Hypertonic Saline (DEVICE), Salbutamol (DRUG).
Who is sponsoring clinical trial NCT03556683?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03556683 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Moderate to Severe Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
CHEST: A Collaboration With Community HEalth Centers to Implement SmarT for Asthma
RECRUITING · Phase 4
-
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma
RECRUITING · Phase 2
-
Leveraging Pharmacogenomics in Asthma for Predication, Mechanism and Endotyping
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.